Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging
Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients
Sponsor: Bayer
Listed as NCT00905879, this observational or N/A phase trial focuses on Magnetic Resonance Imaging and remains completed. Sponsored by Bayer, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Feb 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Feb 2020 [monthly]
Completed
▶ Show 4 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .